Regan MM - Search Results

1

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.

Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Choueiri TK, et al. Among authors: regan mm. Cancer. 2009 Mar 1;115(5):981-7. doi: 10.1002/cncr.24064. Cancer. 2009. PMID: 19152438 Free PMC article.

2

Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma.

Oh WK, Tully P, Kantoff PW, Regan MM. Oh WK, et al. Among authors: regan mm. Cancer. 2003 May 1;97(9):2171-9. doi: 10.1002/cncr.11344. Cancer. 2003. PMID: 12712468 Free article.

3

Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.

Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ. Spentzos D, et al. Among authors: regan mm. Clin Cancer Res. 2003 Aug 15;9(9):3282-7. Clin Cancer Res. 2003. PMID: 12960113 Clinical Trial.

4

Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy.

San Francisco IF, Olumi AF, Yoon JH, Regan MM, DeWolf WC. San Francisco IF, et al. Among authors: regan mm. BJU Int. 2003 Dec;92(9):924-8. doi: 10.1111/j.1464-410x.2003.04506.x. BJU Int. 2003. PMID: 14632848

5

Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.

George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ. George DJ, et al. Among authors: regan mm. Urology. 2004 Feb;63(2):327-32. doi: 10.1016/j.urology.2003.09.059. Urology. 2004. PMID: 14972483

6

Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.

San Francisco IF, Regan MM, Olumi AF, DeWolf WC. San Francisco IF, et al. Among authors: regan mm. J Urol. 2004 Apr;171(4):1492-9. doi: 10.1097/01.ju.0000118690.05943.c0. J Urol. 2004. PMID: 15017206

7

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Atkins M, et al. Clin Cancer Res. 2005 May 15;11(10):3714-21. doi: 10.1158/1078-0432.CCR-04-2019. Clin Cancer Res. 2005. PMID: 15897568

8

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.

Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK. Nakabayashi M, et al. Among authors: regan mm. BJU Int. 2005 Oct;96(6):783-6. doi: 10.1111/j.1464-410X.2005.05714.x. BJU Int. 2005. PMID: 16153200

9

Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.

Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. Nakabayashi M, et al. Among authors: regan mm. Cancer. 2006 Sep 1;107(5):975-81. doi: 10.1002/cncr.22085. Cancer. 2006. PMID: 16862573 Free article.

10

Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.

McDermott DF, Regan MM, Atkins MB. McDermott DF, et al. Among authors: regan mm. Clin Genitourin Cancer. 2006 Sep;5(2):114-9. doi: 10.3816/CGC.2006.n.027. Clin Genitourin Cancer. 2006. PMID: 17026799 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters